当前位置:
X-MOL 学术
›
JAMA Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication.
JAMA Oncology ( IF 28.4 ) Pub Date : 2021-11-01 , DOI: 10.1001/jamaoncol.2021.4757 Jeromie Ballreich 1, 2 , Charles Bennet 3, 4 , Thomas J Moore 2, 5 , G Caleb Alexander 1, 2, 6, 7
中文翻译:
Atezolizumab 用于撤销加速批准适应症的医疗保险支出。
更新日期:2021-09-23
JAMA Oncology ( IF 28.4 ) Pub Date : 2021-11-01 , DOI: 10.1001/jamaoncol.2021.4757 Jeromie Ballreich 1, 2 , Charles Bennet 3, 4 , Thomas J Moore 2, 5 , G Caleb Alexander 1, 2, 6, 7
Affiliation
中文翻译:
Atezolizumab 用于撤销加速批准适应症的医疗保险支出。